- Dec 28, 2016
- Dec 27, 2016Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 DataHERITAGE Study Results Demonstrate Equivalent Overall Response Rate for MYL-1401O in Comparison to Branded Trastuzumab
- Dec 16, 2016Mylan Launches the First Generic for EpiPen® (epinephrine injection, USP) Auto-Injector as an Authorized GenericAuthorized Generic Offered at More Than 50% Below Wholesale Acquisition Cost of EpiPen Auto-Injector
- Nov 10, 2016The Medicines Patent Pool Announces First World Health Organization Prequalification Submissions for Generic DolutegravirCipla and Mylan are the first companies to apply for WHO’s prequalification of dolutegravir
- Nov 9, 2016
- Nov 8, 2016Potential to be First Submission of a Proposed Biosimilar Trastuzumab in the U.S.
- Nov 2, 2016Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)-- Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio --